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Glutamatergic neurotransmission governs excitatory signaling in the mammalian brain, and abnormalities of glutamate signaling have
been shown to contribute to both epilepsy and hyperkinetic movement disorders. The etiology of many severe childhood movement
disorders and epilepsies remains uncharacterized. We describe a neurological disorder with epilepsy and prominent choreoathetosis
caused by biallelic pathogenic variants in FRRS1L, which encodes an AMPA receptor outer-core protein. Loss of FRRS1L function atten-
uates AMPA-mediated currents, implicating chronic abnormalities of glutamatergic neurotransmission in this monogenic neurological
disease of childhood.Pediatric movement disorders encompass a heterogeneous
group of neurodevelopmental and neurodegenerative
disorders affecting movement and limiting activities of
daily living.1 The etiology of many pediatric movement
disorders remains uncharacterized at the current time.
Epileptic-dyskinetic encephalopathies2 (MIM: 308350)
are a recently described class of disorders. Although
these were originally described in association with ARX
(MIM: 300382) mutations,2 mutations in SCN8A3 (MIM:
600702), STXBP14 (MIM: 602926), and FOXG15 (MIM:
164874) have also been found to cause a similar phenotype
characterized by dystonia and/or choreoathetosis, epi-
lepsy, and encephalopathy.
The pathophysiology of choreoathetosis is poorly under-
stood, although a loss of striatal inhibition appears to
be a common mechanism.6 Prior work has implicated
abnormalities of glutamatergic neurotransmission in indi-
viduals with Huntington disease (MIM: 143100), the
most common cause of chorea. This includes a loss of
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 2016 American Society of Human Genetics.cortical8 (AMPA [a-amino-3-hydroxy-5-methyl-4-isoxazo-
lepropionic acid]) glutamatergic receptors in postmortem
brain tissue in individuals with Huntington disease.
AMPA receptors (AMPARs) represent the most common
receptor subtype in the brain and mediate most fast
excitatory post-synaptic potentials. AMPARs also play
important roles in learning and memory via their role in
long-term potentiation. In the case of long-term potentia-
tion, repetitive presynaptic glutamate release leads to
enhanced intracellular sodium concentrations through
AMPAR conduction. This in turn allows for NMDA recep-
tor activation, which itself conducts inwardly directed
calcium currents. Increased levels of intracellular calcium
activate CAMKII (calcium-calmodulin kinase II) activity
and lead to enhanced AMPAR function by both increas-
ing cell-surface AMPAR tracking and phosphorylating
AMPARs.
AMPARs are composed of four subunits, designated
GluR1–GluR4. Functional AMPARs are composed of a
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Figure 1. Families Affected by Choreoathetosis, Epilepsy, and
Cerebral Volume Loss
(A) A total of eight individuals (one deceased) from four unrelated
families are affected by this progressive neurological disease.
(B) Brain MRI shows diffuse cortical and cerebellar volume loss
(long arrows), ex vacuo ventriculomegaly and flattening of the
heads of the caudate nuclei (short arrows), and periventricular
FLAIR (fluid attenuation inversion recovery) hyperintense signal
(arrowheads).of GluR1, GluR2, or GluR3. A variety of post-transcrip-
tional mechanisms contribute to the finely orchestrated
regulation of AMPAR function. Alternative splicing medi-
ates the choice of isoforms (designed flip or flop), whereas
RNA editing effectively limits Ca2þ permeability. In addi-
tion, a host of diverse auxiliary subunits and interacting
proteins also modulate AMPAR properties.
A recent study identified FRRS1L (ferric chelate reductase
1-like) as an important component of the outer core of
AMPAR accessory proteins,9 suggesting that loss of
FRRS1L would affect AMPAR constituency and thus
AMPAR function. Our studies suggest that this indeed is
the case and that pathogenic variants in FRRS1L (aka
C9orf4 [MIM: 604574]) lead to an epileptic-dyskinetic
encephalopathy.
In our study, the index family hails from southern Saudi
Arabia. The parents are distant cousins (Figure 1A). All five1250 The American Journal of Human Genetics 98, 1249–1255, Juneof the couple’s children exhibit encephalopathy, epilepsy,
and progressive choreoathetosis (Table 1). One child (indi-
vidual 1_II-2) had already succumbed to the disease at the
time of ascertainment. All children were born at term
without complications. All had normal early development
but began to regress between the ages of 18 and 22months,
when they ceased to walk and lost expressive language.
This coincided with the onset of hemiclonic and tonic-
clonic seizures, which showed some response to carba-
mazepine and/or valproate. Examinations disclosed no
dysmorphic features, normal fundi, global developmental
delay, diffuse hypotonia, and generalized chorea with a
paucity of volitional movement. Routine laboratory
screening was unremarkable, as was triplet repeat analysis
ofHTT (MIM: 613004). BrainMRI was initially normal, but
repeat neuroimaging demonstrated diffuse cortical and
cerebellar volume loss and flattening of the caudate heads
(Figure 1B). All of the affected children became less
responsive to their environment over time, and their hy-
perkinetic movement disorder gradually gave way to a
rigid, akinetic state in late adolescence.
Given the family structure and putative autosomal-
recessive nature of the disorder, we then applied tandem
homozygosity mapping and whole-exome sequencing.
Family members were enrolled in our institutional-re-
view-board-approved protocol after written informed con-
sent was obtained. Genomic DNA was extracted from
whole blood, and homozygous regions shared by affected
individuals but absent in unaffected individuals in family 1
were identified with Affymetrix Whole-Genome CytoScan
HD SNP arrays according to the manufacturer’s instruc-
tions. We identified six>3Mb homozygous regions shared
by affected family members alone (Table S1).
We performed whole-exome sequencing on individuals
1_II-1 to 1_II-4 and focused our analysis on homozy-
gous stop-gain, stop-loss, or frameshift and splice-site or
missense variants predicted to be deleterious. Exonic tar-
gets were enriched with the SeqCap EZ Human Exome
Library v.2.0 (Nimblegen), and sequencing was performed
on an Illumina HiSeq 2500 according to the manufac-
turer’s instructions for the generation of paired-end reads.
Average coverage depth was >703 within the targeted
exome. Sequencing reads were aligned to the NCBI human
reference genome (GRCh37) with the Burrow-Wheeler
Aligner (0.7.10). Picard Tools (1.111) was subsequently
used for sorting and marking duplicates. Local realign-
ment, base-quality-score recalibration, and variant calling
were performed with the Genome Analysis Toolkit
(GATK 3.3.-0), and variant-call files were evaluated with
NextCode or Cartagenia Bench Lab next-generation
sequencing software. Filtering included removing low-
quality calls (Illumina threshold < 20) and variants with
a minor allele frequency > 0.01 in the Exome Aggrega-
tion Consortium (ExAC) Browser and NHLBI Exome
Sequencing Project (ESP) Exome Variant Server while prior-
itizing homozygous variants predicted to be deleterious by
SIFT, PolyPhen-2, MutationTaster, and CADD.2, 2016
Table 1. Clinical Features of Individuals with FRRS1L Mutations
Individual Mutation
Age at
Onset Regression
Intellectual
Impairment
Movement
Disorder Epilepsy
Neuromotor
Impairment Other
1_II-1 c.961C>T
(p.Gln321*)
18 months yes severe; no
expressive
speech
chorea; later
rigidity,
hypokinesia
generalized tonic-
clonic seizures
spasticity; impaired
volitional movement
–
1_II-2 c.961C>T
(p.Gln321*)
22 months yes severe; no
expressive
speech
chorea; later
rigidity,
hypokinesia
hemiclonic seizures;
later generalized
spasticity; impaired
volitional movement
died at
16 years
of age
1_II-3 c.961C>T
(p.Gln321*)
22 months yes severe; no
expressive
speech
chorea; later
rigidity,
hypokinesia
hemiclonic seizures spasticity; impaired
volitional movement
–
1_II-4 c.961C>T
(p.Gln321*)
22 months yes severe; no
expressive
speech
chorea; later
rigidity,
hypokinesia
generalized seizures;
hemiclonic seizures
spasticity; impaired
volitional movement
–
1_II-5 c.961C>T
(p.Gln321*)
24 months no severe; no
expressive
speech
chorea hemiclonic seizures – –
2_II-1 c.845G>A
(p.Trp282*)
4 months no severe; no
expressive
speech
chorea;
ballism
multifocal; intractable hypotonia; impaired
volitional movement
–
3_II-1 c.737_739del
(p.Gly246del)
24 months yes severe; no
expressive
speech
chorea;
cogwheel
rigidity
juvenile spasms
evolved to Lennox-
Gastaut syndrome
hypotonia; impaired
volitional movement
horizontal
and vertical
nystagmus
4_II-2 c.436dup
(p.Ile146Asnfs*10)
6 months yes severe; no
expressive
speech
chorea;
myoclonus
multifocal; clonic hypotonia; no
volitional movement
–
Figure 2. Variants in Human FRRS1L and Effects on Protein
Abundance
(A) The three variants leading to premature truncation codons
are all predicted to lead to loss of the FRRS1L transmembrane
(TM) domain, whereas p.Ile146Asnfs*10 and p.Gly246del are pre-
dicted to disrupt the predicted transmembrane and extracellular
DOMON (dopamine beta-monooxygenase N-terminal) domain
(InterPro: IPR005018).
(B) Immunoblot in affected fibroblasts demonstrates lower
amounts of FRRS1L in individuals with premature stop variants
than in age- and sex-matched control individuals (representative
image); anti-FRRS1L (1:1,000, Atlas, Sigma-Aldrich) and anti-
b-actin (1:1,000, Santa Cruz) served as loading controls.Using this strategy, we identified a homozygous
c.961C>T (p.Gln321*) variant (GenBank: NM_014334.2)
in FRRS1L within a prominent block of homozygosity
(chr9: 104,622,396–119,149,440; UCSC Genome Browser
hg19). We confirmed segregation within affected family
members by Sanger sequencing (Figure 1A). This variant
has not been reported in variant repositories and is pre-
dicted to lead to loss of a C-terminal hydrophobic motif
that might contribute to FRRS1L’s membrane localization
(Figure 2A).
We subsequently identified three additional, unrelated
individuals with similar phenotypes and biallelic FRRS1L
variants by whole-exome sequencing (Table 1) and
confirmed sequence changes by Sanger sequencing
(Figure 1A). None of these variants has been identified in
public repositories. Individual 4_II-2 was the most severely
affected.
Individual 2_II-1, an unrelated girl, was born to non-
consanguineous parents of mixed European descent after
an unremarkable pregnancy at 31 weeks of gestation. At
4 months of age, she started having choreoathetotic move-
ments of her hands, opisthotonic posturing, and occa-
sional hand tremors. She reached developmental motor
and language milestones until the age of 13 months,
when she began to have generalized tonic-clonic seizures.
During periods of illness, her seizures were accompanied
by chaotic eye movements and forced gaze deviation,
frequent episodes of tone loss, fluctuating levels of alert-
ness, and truncal hypotonia. Between 14 and 27 months
of age, her seizures remained refractory to levetiracetam,The Americphenobarbital, clobazam, and the ketogenic diet. This
was associated with developmental regression, and she re-
mained nonverbal with diminished volitional movement.
Her examination was significant for generalized chorea
and ballism (Movie S1). Whole-exome sequencing identi-
fied a homozygous c.845G>A (p.Trp282*) change in
FRRS1L.an Journal of Human Genetics 98, 1249–1255, June 2, 2016 1251
Figure 3. Frrs1l Expression Pattern
Murine Frrs1l expression detected by lacZ
reporter. Frrs1l is expressed throughout
the adult brain, predominantly in the cer-
ebellum (A) and differentially throughout
layers of the cortex (B), thalamus (C), hip-
pocampus (D), substantia nigra (E), and
anterior olfactory nucleus (F). There is
expression in the dorsal horn of the lum-
bar spinal cord (G) and the trigeminal gan-
glion (H). Outside of the nervous system,
Frrs1l is expressed in the epididymis (I)
and seminiferous tubules (J) of the testis.
During development (E12.5), Frrs1l is ex-
pressed in the ventral forebrain (K) and
weakly in the spinal cord (L).Individual 3_II-1, a Puerto Rican girl with no recognized
consanguinity, was born at an estimated 37 weeks of gesta-
tion. She began to cruise with an uncoordinated gait at
11 months and used several words appropriately before
experiencing a neurodevelopmental regression at the age
of 24months. She developed juvenile spasms and was later
diagnosed with Lennox-Gastaut syndrome. She initially
benefited from the ketogenic diet, but her seizures were
never fully controlled. Examination revealed horizontal
and vertical nystagmus with esotropia, generalized chorea
and cogwheel rigidity of her upper limbs, hyperreflexia,
hypotonia, and diminished volitional movement (she
did not reach purposefully or have a means of locomo-
tion). No expressive language was evident. A homozygous
in-frame deletion (c.737_739del [p.Gly246del]) was identi-
fied by whole-exome sequencing. This variant was pre-
dicted to be deleterious by PROVEAN (score ¼ 7.386).
Individual 4_II-1, an unrelated girl, was born at term by
caesarean section to consanguineous Moroccan parents
after a pregnancy complicated by gestational diabetes.
Poor muscle tone was noted from early infancy, and she
never attained good head control. She was delayed in
reaching early motor milestones. At the age of 10 months,
she could fix and follow objects, albeit with saccadic pur-
suit, and could grasp nearby objects and bring them to
her mouth. She demonstrated choreoathetosis of her
arms and hands. Her alertness fluctuated, putatively
related to hypomotor seizures. These proved resistant to
levetiracetam, valproic acid, and vigabatrin, and her eye
contact and muscle tone deteriorated. At the age of
17 months, she developed status epilepticus. Phenobar-
bital led to satisfactory seizure control, and now she has
mainly short, multifocal clonic seizures and intermittent
myoclonus. She is currently fed via nasogastric tube.1252 The American Journal of Human Genetics 98, 1249–1255, June 2, 2016Expressive speech is absent. A homo-
zygous variant in FRRS1L (c.436dup
[p.Ile146Asnfs*10]) was identified by
whole-exome sequencing.
Targeted sequencing of FRRS1L in a
cohort of 52 pediatric and adult indi-
viduals with early-onset Huntington-like disease and lacking triplet repeat expansions in HTT
did not identify any predicted pathogenic alleles. Expand-
ing our analysis to >500 in-house exomes of individuals
with neurodegenerative disease of unknown etiology re-
vealed four alleles predicted to be deleterious in the hetero-
zygous form (Table S2). No biallelic FRRS1L variants
predicted to be deleterious were detected in datasets from
the Epi4K and EuroEPINOMICS-RES consortia.
Although FRRS1L is predominantly expressed in the
brain, it is expressed at a lower level in fibroblasts (Fig-
ure 2B), as are AMPARs.10 Using affected fibroblasts
and age- and sex-matched controls, we next determined
that FRRS1L amounts were markedly reduced in both
p.Gln321*- and p.Trp282*-affected cells (Figure 2B). Given
that the c.961C>T variant is found within the final exon of
the transcript, we sought to determine whether this mRNA
escapes nonsense-mediated decay. We found comparable
levels of both control and mutant transcripts (Figure S1),
indicating that the decreased abundance of FRRS1L in
c.961C>T-affected cells is most likely related to post-tran-
scriptional mechanisms.
Given the severe neurological phenotype in the affected
individuals, we next evaluated Frrs1l expression in em-
bryos and adultmice by using a lacZ reporter. In embryonic
day 12.5 (E12.5) embryos, Frrs1l expression was evident in
the ventral forebrain, but a lower level of expression was
seen in the remainder of the embryos. Frrs1l expression
was highest in the adult brain in the cortex, cerebellum,
hippocampus, and basal ganglia (Figure 3). This is consis-
tent with prior reports of robust expression in multiple
brain regions, including the striatum, thalamus, and cor-
tex.7,8 Developmentally, FRRS1L might play a role in
neuronal maturation, given that AMPARs promote the for-
mation andmaturation of synapses during development.11
Figure 4. Effects of FRRS1L Loss on Elec-
trophysiology
(A) siRNA knockdown of FRRS1L in neuro-
nally differentiated SH-SY5Y cells led to
FRRS1L amounts comparable to those
seen in affected fibroblasts (n ¼ 3); tran-
sient receptor potential channel 1 (1:500,
Alomone) and b-actin served as loading
controls.
(B) siFRRS1L-treated cells showed de-
creased Ca2þ influx after stimulation with
100 mM AMPA (representative tracing).
(C) Mean Ca2þ influx was significantly de-
creased by FRRS1L knockdown (mean 5
SEM; n ¼ 30–50 cells per condition;
*p < 0.05).
(D) A bath applied 100 mM AMPA-induced
inward currents to control and siFRRS1L
cells at a holding potential of 80 mV
(representative tracings).
(E) Current-voltage (I-V) curves under the
conditions in (D).
(F) Mean current intensity at 80 mV
(mean 5 SEM; n ¼ 8–10 recordings per
condition; *p < 0.05).Little is known about the biological function of FRRS1L.
Despite its name (ferric chelate reductase 1-like), it lacks a
ferrochelatase domain and so is unlikely to function in
iron storage and processing. In a prior study, FRRS1L co-
immunoprecipitated with GluR1, suggesting a direct inter-
action between the two proteins.9 We thus sought to
determine whether the loss of FRRS1L in affected individ-
uals could affect AMPAR function. The human sympathoa-
drenal cell line SH-SY5Y can be differentiated to a neuronal
phenotype with the use of retinoic acid; these cell lines ex-
press subunits GluR1–GluR4 of AMPAR.12 Using neuro-
nally differentiated SH-SY5Y cells and siRNA, we knocked
down FRRS1L, leading to reduced FRRS1L amounts analo-
gous to those seen in affected cells (Figure 4A). We next
performed a series of patch-clamp experiments with a
focus on AMPA-mediated currents. We found that loss of
FRRS1L significantly attenuated calcium influx (Figures
4B and 4C) and diminished AMPA-induced inward cur-
rents (Figures 4D–4F).
Ourfindings implicate FRRS1Las an importantmodulator
of glutamate signaling with substantial implications in
health and disease. AMPAR complexity is only now begin-The American Journal of Human Gening to be appreciated, given that
dozens of auxiliary subunits govern
ion-channel gating properties, and
dynamic changes in AMPAR compo-
sition are likely to affect localization
and abundance within the syn-
apse.13–15 FRRS1L is an outer-core pro-
tein that is thought to functionwithin
the AMPAR and directly interact with
inner-core components.9 The signifi-
cant diminution of AMPA-mediated
currents we observed with FRRS1Lknockdown points to an important role for the protein in
normal AMPAR function, and its relevance has not previ-
ously been appreciated. Additional studies are needed to
determine whether FRRS1L influences AMPAR function by
modulating trafficking or by influencing channel gating
properties more directly. FRRS1L could also have other roles
outside of its interaction with glutamate receptors.
Our findings suggest that loss-of-function pathogenic
variants might impair normal glutamatergic neurotrans-
mission and thus lead to choreoathetosis, epilepsy, and
persistent encephalopathy related to chronic disruption
of normal neuronal-circuit function. Interestingly, patho-
genic STXBP1 variants, which also lead to an epileptic-
dyskinetic encephalopathy, putatively impair normal
SNARE (soluble N-ethylmaleimide-sensitive factor attach-
ment protein receptor)-mediated neurotransmitter release,
including glutamate exocytosis into the synaptic cleft.16
Pathogenic variants in another AMPAR outer-core compo-
nent, PRRT2 (MIM: 614386), have been shown to lead to
seizures and choreoathetosis in affected individuals.17
Individuals with mutations in PRRT2 generally have
paroxysmal symptoms rather than a progressive course,netics 98, 1249–1255, June 2, 2016 1253
but such cases typically involve heterozygous pathogenic
variants rather than the homozygous pathogenic variants
we observed in our individuals. The recent identification
of individuals with biallelic PRRT2 mutations suggests a
more severe phenotype in such individuals.18 The identifi-
cation of additional individuals with pathogenic variants
in FRRS1L or related AMPAR core proteins will help shed
light on the role of these accessory proteins in modulating
glutamatergic signaling in the CNS, whose complexities
are now beginning to be unraveled.19Accession Numbers
The accession numbers for the pathogenic FRRS1L variants re-
ported in this paper are ClinVar: SCV000257326 (c.961C>T),
SCV000257327 (c.845G>A), SCV000257328 (c.737_739del), and
SCV000257329 (c.436dup).Supplemental Data
Supplemental Data include one figure, two tables, and one movie
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